Sabine Brookman‐May

Author

Sabine Brookman‐May

Ludwig-Maximilians-Universität München ORCID

Also Known As

Christian Stief, F. M. Wagenlehner, J Langenhuijsen, Martin Kees, Philipp J. Spachmann, S Brookman-May, S. Brookman-May, S. D. Brookman-May, S.D. Brookman-May, Sabine Brookman-May

256

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Ludwig-Maximilians-Universität München Barmherzige Brüder Klinikum St. Elisabeth in Straubing University of Regensburg Heidelberg University Medical University of Graz

About

Sabine Brookman‐May is an author at Ludwig-Maximilians-Universität München specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	37	1.7K
2	Engineering	2	2	51
3	Health Sciences	2	2	66
4	Public Health	1	1	46
5	Endocrinology	1	1	46

Sabine Brookman‐May

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study Kim N., Simon Chowdhury, Anders Bjartell, Journal of Clinical Oncology	2021	469
Apalutamide and Overall Survival in Prostate Cancer Matthew R. Smith, Fred Saad, Simon Chowdhury, European Urology	2020	277
Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort Atiqullah Aziz, Matthias May, Maximilian Burger, European Urology Radical CystectomyUrologySurgical OncologyGenitourinary CancerMedicine	2014	203
Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy Matthias May, Edwin Herrmann, Christian Bolenz, Annals of Surgical Oncology Urological ResearchUrologySurgical OncologyUrologic Cancer EpidemiologyGenitourinary Cancer	2011	133
Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project) Sabine Brookman‐May, Matthias May, Shahrokh F. Shariat, European Urology UrologySurgical OncologyRisk ModelGenitourinary CancerMedicine	2012	104
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study Fred Saad, Eleni Efstathiou, Gerhardt Attard, The Lancet Oncology UrologyOncologyPrednisone Versus PlaceboAbiraterone AcetateMedicine	2021	103
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer S. Chowdhury, Anders Bjartell, Neeraj Agarwal, Annals of Oncology	2023	98
Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study Andrea Minervini, Riccardo Campi, Brian R. Lane, The Journal of Urology	2019	91
Lymph Node Density Affects Cancer-Specific Survival in Patients with Lymph Node–Positive Urothelial Bladder Cancer Following Radical Cystectomy Matthias May, Edwin Herrmann, Christian Bolenz, European Urology Urological ResearchUrologySurgical OncologyGenitourinary CancerMedicine	2011	88
External Validation of Postoperative Nomograms for Prediction of All-Cause Mortality, Cancer-Specific Mortality, and Recurrence in Patients With Urothelial Carcinoma of the Bladder Philipp Nuhn, Matthias May, Maxine Sun, European Urology External ValidationUrologySurgical OncologyCancer-specific MortalityPostoperative Nomograms	2011	86

Page 1